Peter LeWitt

Summary

Affiliation: Henry Ford Hospital
Country: USA

Publications

  1. doi request reprint Recent advances in CSF biomarkers for Parkinson's disease
    Peter LeWitt
    Department of Neurology, Henry Ford Hospital, Michigan 48322, USA
    Parkinsonism Relat Disord 18:S49-51. 2012
  2. doi request reprint Tardive dyskinesia caused by tetrabenazine
    Peter A LeWitt
    Departments of Neurology, Henry Ford Hospital and Wayne State University School of Medicine, Detroit, MI 48322, USA
    Clin Neuropharmacol 36:92-3. 2013
  3. pmc Rotigotine transdermal system for long-term treatment of patients with advanced Parkinson's disease: results of two open-label extension studies, CLEOPATRA-PD and PREFER
    Peter A LeWitt
    Department of Neurology, Henry Ford Hospital, Detroit, MI, USA
    J Neural Transm 120:1069-81. 2013
  4. doi request reprint Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study)
    Peter A LeWitt
    Departments of Neurology, Henry Ford Hospital, Detroit, MI, USA
    Neurology 79:163-9. 2012
  5. doi request reprint Actively transported levodopa prodrug XP21279: a study in patients with Parkinson disease who experience motor fluctuations
    Peter A LeWitt
    Department of Neurology, Henry Ford Hospital, West Bloomfield, MI 48322, USA
    Clin Neuropharmacol 35:103-10. 2012
  6. doi request reprint CSF xanthine, homovanillic acid, and their ratio as biomarkers of Parkinson's disease
    Peter LeWitt
    Department of Neurology, Henry Ford Hospital, 2799 West Grand Boulevard, Detroit, MI 48202, USA
    Brain Res 1408:88-97. 2011
  7. ncbi request reprint Rotigotine: a viewpoint by Peter LeWitt
    Peter LeWitt
    Department of Neurology, Wayne State University School of Medicine, Detroit, Michigan and the Clinical Neuroscience Center, Southfield, MI, USA
    CNS Drugs 19:983-4. 2005
  8. ncbi request reprint Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial
    Robert G Holloway
    Department of Neurology, University of Rochester, 1351 Mt Hope Avenue, Suite 220, Rochester, NY 14620, USA
    Arch Neurol 61:1044-53. 2004
  9. pmc Impact of belief in neuroprotection on therapeutic intervention in Parkinson's disease
    Rodger J Elble
    Department of Neurology, Southern Illinois University School of Medicine, Springfield, Illinois, USA
    Mov Disord 25:1082-6. 2010
  10. ncbi request reprint Levodopa in the treatment of Parkinson's disease: current controversies
    C Warren Olanow
    Department of Neurology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Mov Disord 19:997-1005. 2004

Collaborators

Detail Information

Publications12

  1. doi request reprint Recent advances in CSF biomarkers for Parkinson's disease
    Peter LeWitt
    Department of Neurology, Henry Ford Hospital, Michigan 48322, USA
    Parkinsonism Relat Disord 18:S49-51. 2012
    ..The ultimate goal is for CSF biomarkers also found in peripheral biospecimens, aiding in diagnostic screening applications and providing further clues as to the etiology of PD...
  2. doi request reprint Tardive dyskinesia caused by tetrabenazine
    Peter A LeWitt
    Departments of Neurology, Henry Ford Hospital and Wayne State University School of Medicine, Detroit, MI 48322, USA
    Clin Neuropharmacol 36:92-3. 2013
    ..There have been no prior reports of tardive dyskinesia with this drug...
  3. pmc Rotigotine transdermal system for long-term treatment of patients with advanced Parkinson's disease: results of two open-label extension studies, CLEOPATRA-PD and PREFER
    Peter A LeWitt
    Department of Neurology, Henry Ford Hospital, Detroit, MI, USA
    J Neural Transm 120:1069-81. 2013
    ..2 points below baseline, respectively, at end of treatment. In these open-label studies, adjunctive rotigotine was efficacious with an acceptable safety and tolerability profile in patients with advanced PD for up to 6 years...
  4. doi request reprint Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study)
    Peter A LeWitt
    Departments of Neurology, Henry Ford Hospital, Detroit, MI, USA
    Neurology 79:163-9. 2012
    ..The primary study objective was to assess suppression of LID by fipamezole at day 28, as measured by the levodopa-induced dyskinesia scale (LIDS), a modification of the abnormal involuntary movement scale...
  5. doi request reprint Actively transported levodopa prodrug XP21279: a study in patients with Parkinson disease who experience motor fluctuations
    Peter A LeWitt
    Department of Neurology, Henry Ford Hospital, West Bloomfield, MI 48322, USA
    Clin Neuropharmacol 35:103-10. 2012
    ....
  6. doi request reprint CSF xanthine, homovanillic acid, and their ratio as biomarkers of Parkinson's disease
    Peter LeWitt
    Department of Neurology, Henry Ford Hospital, 2799 West Grand Boulevard, Detroit, MI 48202, USA
    Brain Res 1408:88-97. 2011
    ..These observations add to other neurochemical evidence that links purine metabolism to Parkinson's disease...
  7. ncbi request reprint Rotigotine: a viewpoint by Peter LeWitt
    Peter LeWitt
    Department of Neurology, Wayne State University School of Medicine, Detroit, Michigan and the Clinical Neuroscience Center, Southfield, MI, USA
    CNS Drugs 19:983-4. 2005
  8. ncbi request reprint Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial
    Robert G Holloway
    Department of Neurology, University of Rochester, 1351 Mt Hope Avenue, Suite 220, Rochester, NY 14620, USA
    Arch Neurol 61:1044-53. 2004
    ..The best way to initiate dopaminergic therapy for early Parkinson disease remains unclear...
  9. pmc Impact of belief in neuroprotection on therapeutic intervention in Parkinson's disease
    Rodger J Elble
    Department of Neurology, Southern Illinois University School of Medicine, Springfield, Illinois, USA
    Mov Disord 25:1082-6. 2010
    ..We found the investigators' level of confidence in these agents had no effect on the time to symptomatic therapy or on the change in UPDRS during 12 months of treatment...
  10. ncbi request reprint Levodopa in the treatment of Parkinson's disease: current controversies
    C Warren Olanow
    Department of Neurology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Mov Disord 19:997-1005. 2004
    ..Clinical trials to test this hypothesis are underway. We review current evidence relating to these areas of controversy...
  11. doi request reprint Abnormal apocrine secretory cell mitochondria in a Huntington disease patient
    Christos Sidiropoulos
    Department of Neurology, Henry Ford Hospital, Wayne State University School of Medicine, Detroit, MI 48322, USA
    J Neurol Sci 323:261-3. 2012
    ..Biopsies from other HD patients have shown similar mitochondrial changes in cerebral neurons, muscle, fibroblasts, and lymphoblasts, adding to evidence for a systemic disturbance of mitochondria in HD...
  12. doi request reprint Comparison of dysphagia before and after deep brain stimulation in Parkinson's disease
    Alice K Silbergleit
    Division of Speech Language Sciences and Disorders, Department of Neurology, Henry Ford Health System, Detroit, Michigan 48322, USA
    Mov Disord 27:1763-8. 2012
    ..Subjects with advanced PD who are undergoing DBS may perceive significant improvement in swallowing ability despite the lack of objective improvements in swallowing function...